Wednesday, February 25 2026

Pharma firms introduce advanced medications to help patients control diabetes, obesity
Pharmaceutical firms in Pakistan recently introduced advanced GLP-1- and GIP-based medications for people living with chronic diabetes amid the health crisis escalating to an alarming level with one in three adults reported living with high blood sugar, making Pakistan the third most affected country in the world. In addition to imports, some pharmaceutical firms started manufacturing and supplying the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)-based medications locally to help control type 2 diabetes and obesity in the country, it was learnt. According to the government, World Health Organisation (WHO), and International Diabetes Federation (IDF) statistics of 2025, there are 34.5 million people living with diabetes in Pakistan.
Related news categories: business economic-indicators misc pharma